U.S. to limit states’ access to COVID antibody treatments as demand rises … Aggressively reducing Alzheimer’s risk factors could mean 1.2 million fewer cases in 2050: experts … NIH launches nationwide...
SNF-linked wound clinics saw fewer patients during pandemic but unchanged outcomes
By
Alicia Lasek
Nov 10, 2021
Investigators expected that wound outcomes would be adversely affected by pandemic disruptions. But data from hundreds of wound care clinics in the United States show otherwise.
CDC: Turn to Paxlovid to treat COVID-19, not steroids or antibiotics
By
Alicia Lasek (f3)
Apr 26, 2022
The agency is urging clinicians to consider the now readily available, recommended therapies such as Paxlovid as first-line COVID-19 treatments.
Nursing home study reveals ‘dramatic’ fluctuations in prescribing of COVID-19 meds
By
Alicia Lasek
May 26, 2023
Investigators tracked the use of COVID-19 medications in 11 U.S. nursing home chains, describing prescribing patterns that shed new light on the challenges of pandemic clinical care.
Lab responsible for COVID testing errors at dozens of nursing homes faces possible federal sanctions
By
Danielle Brown
Oct 20, 2020
A Massachusetts laboratory responsible for COVID-19 testing errors at several nursing homes could face fines of up to $10,000 per day for lab practices that jeopardized the safety of residents.
Also in the News for Wednesday, Jan. 4
By
Kimberly Marselas
Jan 04, 2023
COVID hospitalizations approach last summer’s high, but flu and RSV cases waning … NC nursing home to pay $126K after storm-related staff shortages, two patient deaths … FDA decision on experimental...
25 percent of COVID patients have post-acute symptoms; Report highlights emerging care needs
By
Alicia Lasek
Jun 18, 2021
A analysis based on nearly two million private U.S. healthcare claims has identified the most common post-COVID conditions with a focus on age, gender, mental health conditions and mortality. Even 19%...
Feds identify promising and ‘urgently needed’ COVID antiviral drug
By
Alicia Lasek
Jun 04, 2021
The experimental drug TEMPOL has shown promise in early studies, halting the activity of a viral enzyme and limiting the severity of SARS-CoV-2 infections.
An antibody cocktail that halts disease progression in sick COVD-19 patients has been shown to prevent the disease altogether in healthy people who live in close contact with an infected person, the drugmaker...
More clinical benefits of molnupiravir ID’d in COVID-19
Jun 07, 2022
New benefits for certain COVID-19 patients, including reduced need for respiratory intervention, have been found for Merck’s COVID-19 pill molnupiravir.